BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 21163254)

  • 1. Cis-4-methylsphingosine is a sphingosine-1-phosphate receptor modulator.
    Ter Braak M; Claas RF; Hegen B; Labocha S; Ferreirós N; Pfeilschifter J; Huwiler A; van Echten-Deckert G; Meyer Zu Heringdorf D
    Biochem Pharmacol; 2011 Mar; 81(5):617-25. PubMed ID: 21163254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Lee CW; Choi JW; Chun J
    Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets.
    Huwiler A; Pfeilschifter J
    Biochem Pharmacol; 2008 May; 75(10):1893-900. PubMed ID: 18321471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow.
    Maeda Y; Seki N; Sato N; Sugahara K; Chiba K
    Int Immunol; 2010 Jun; 22(6):515-25. PubMed ID: 20497959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists.
    Clemens JJ; Davis MD; Lynch KR; Macdonald TL
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3568-72. PubMed ID: 15982878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FTY720 modulates human oligodendrocyte progenitor process extension and survival.
    Miron VE; Jung CG; Kim HJ; Kennedy TE; Soliven B; Antel JP
    Ann Neurol; 2008 Jan; 63(1):61-71. PubMed ID: 17918267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sphingosine-1-phosphate-induced airway hyper-reactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor.
    Trifilieff A; Fozard JR
    J Pharmacol Exp Ther; 2012 Aug; 342(2):399-406. PubMed ID: 22570366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.
    Brinkmann V
    Pharmacol Ther; 2007 Jul; 115(1):84-105. PubMed ID: 17561264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.
    LaMontagne K; Littlewood-Evans A; Schnell C; O'Reilly T; Wyder L; Sanchez T; Probst B; Butler J; Wood A; Liau G; Billy E; Theuer A; Hla T; Wood J
    Cancer Res; 2006 Jan; 66(1):221-31. PubMed ID: 16397235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTY720 inhibits S1P-mediated endothelial healing: relationship to S1P1-receptor surface expression.
    Krump-Konvalinkova V; Chwalla I; Siess W
    Biochem Biophys Res Commun; 2008 Jun; 370(4):603-8. PubMed ID: 18402775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of cell motility observed with high doses of sphingosine 1-phosphate or phosphorylated FTY720 involves RGS2 through its interactions with the receptor S1P.
    Kohno T; Igarashi Y
    Genes Cells; 2008 Jul; 13(7):747-57. PubMed ID: 18513330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
    Chiba K
    Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes.
    Forrest M; Sun SY; Hajdu R; Bergstrom J; Card D; Doherty G; Hale J; Keohane C; Meyers C; Milligan J; Mills S; Nomura N; Rosen H; Rosenbach M; Shei GJ; Singer II; Tian M; West S; White V; Xie J; Proia RL; Mandala S
    J Pharmacol Exp Ther; 2004 May; 309(2):758-68. PubMed ID: 14747617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective activation of G alpha i mediated signalling of S1P3 by FTY720-phosphate.
    Sensken SC; Stäubert C; Keul P; Levkau B; Schöneberg T; Gräler MH
    Cell Signal; 2008 Jun; 20(6):1125-33. PubMed ID: 18313900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
    Butler J; Lana D; Round O; LaMontagne K
    Prostaglandins Other Lipid Mediat; 2004 Jan; 73(1-2):29-45. PubMed ID: 15165029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor.
    Walter DH; Rochwalsky U; Reinhold J; Seeger F; Aicher A; Urbich C; Spyridopoulos I; Chun J; Brinkmann V; Keul P; Levkau B; Zeiher AM; Dimmeler S; Haendeler J
    Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):275-82. PubMed ID: 17158356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors.
    Gräler MH; Goetzl EJ
    FASEB J; 2004 Mar; 18(3):551-3. PubMed ID: 14715694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist.
    Murakami A; Takasugi H; Ohnuma S; Koide Y; Sakurai A; Takeda S; Hasegawa T; Sasamori J; Konno T; Hayashi K; Watanabe Y; Mori K; Sato Y; Takahashi A; Mochizuki N; Takakura N
    Mol Pharmacol; 2010 Apr; 77(4):704-13. PubMed ID: 20097776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
    Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
    Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.